POWEL H BROWN to Disease Models, Animal
This is a "connection" page, showing publications POWEL H BROWN has written about Disease Models, Animal.
Connection Strength
0.328
-
Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib. Cancer Prev Res (Phila). 2009 Feb; 2(2):168-74.
Score: 0.128
-
Transgenic mouse models for the prevention of breast cancer. Mutat Res. 2005 Aug 25; 576(1-2):93-110.
Score: 0.101
-
The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges. Cancer Prev Res (Phila). 2008 Aug; 1(3):161-6.
Score: 0.031
-
The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin Cancer Res. 2006 Oct 01; 12(19):5902-9.
Score: 0.027
-
Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002 May; 11(5):467-74.
Score: 0.020
-
Hepatic stem cells and transforming growth factor ? in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2012 Sep; 9(9):530-8.
Score: 0.010
-
Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models. Breast Cancer Res. 2007; 9(1):R12.
Score: 0.007
-
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.
Score: 0.005